LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Open

40.57 -3.57

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

40.15

Max

42.07

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Gewinnspanne	-1,582.642
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+2.37% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	4B 6.2B
Vorheriger Eröffnungskurs	44.14
Vorheriger Schlusskurs	40.57

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Dez. 2025, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13. Dez. 2025, 00:04 UTC

Akquisitionen, Fusionen, Übernahmen

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14. Dez. 2025, 23:46 UTC

Market Talk

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14. Dez. 2025, 23:36 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14. Dez. 2025, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue to Take Full Control of US$101M Copper Miner Alta

14. Dez. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14. Dez. 2025, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14. Dez. 2025, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14. Dez. 2025, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue to Acquire Remaining 64% of Alta Copper

14. Dez. 2025, 17:00 UTC

Ergebnisse

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14. Dez. 2025, 08:30 UTC

Akquisitionen, Fusionen, Übernahmen

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13. Dez. 2025, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. Dez. 2025, 08:00 UTC

Akquisitionen, Fusionen, Übernahmen

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. Dez. 2025, 07:00 UTC

Akquisitionen, Fusionen, Übernahmen

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13. Dez. 2025, 00:24 UTC

Akquisitionen, Fusionen, Übernahmen

Want a Piece Of SpaceX? -- Barrons.com

12. Dez. 2025, 23:49 UTC

Akquisitionen, Fusionen, Übernahmen

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. Dez. 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. Dez. 2025, 22:32 UTC

Ergebnisse

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Dez. 2025, 20:45 UTC

Ergebnisse

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. Dez. 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. Dez. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. Dez. 2025, 19:23 UTC

Ergebnisse

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. Dez. 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. Dez. 2025, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. Dez. 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. Dez. 2025, 17:49 UTC

Ergebnisse

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. Dez. 2025, 17:34 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

2.37% Vorteil

12-Monats-Prognose

Durchschnitt 43.11 USD 2.37%

Hoch 53 USD

Tief 30 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.